BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feldman SR, Lacy FA, Huang WW. The safety of treatments used in pyoderma gangrenosum. Expert Opinion on Drug Safety 2018;17:55-61. [DOI: 10.1080/14740338.2018.1396316] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Huang X, Han K, Xue R, Li L, Zeng K, Liang L. Successful treatment with oral methylprednisolone and cyclosporine for refractory pyoderma gangrenosum in children: Report of a case and review of the literature. Clin Case Rep 2020;8:416-9. [PMID: 32185026 DOI: 10.1002/ccr3.2263] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Rodríguez-Zúñiga MJM, Heath MS, Gontijo JRV, Ortega-Loayza AG. Pyoderma gangrenosum: a review with special emphasis on Latin America literature. An Bras Dermatol 2019;94:729-43. [PMID: 31789268 DOI: 10.1016/j.abd.2019.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
3 Janowska A, Oranges T, Fissi A, Davini G, Romanelli M, Dini V. PG-TIME: A practical approach to the clinical management of pyoderma gangrenosum. Dermatol Ther 2020;33:e13412. [PMID: 32291879 DOI: 10.1111/dth.13412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Saffie MG, Shroff A. A Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe. Case Rep Infect Dis 2018;2018:8907542. [PMID: 29854503 DOI: 10.1155/2018/8907542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]